MTOR and tuberous sclerosis: This increased use of approved mTOR inhibitor, everolimus, and the wider evaluation of surgery candidates in the management of TSC-associated focal seizures and in some individuals with drug-resistant infantile spasms might improve responder rates in the future and could help to achieve a better cognitive TAND outcomes.